pharmaphorum

NOVEMBER 22, 2020

Formed in 2011 by David Rowley and chief operating officer Sandy Royden, OPEN Health has pursued several M&A deals over the years, with the most recent including a merger with med comms provider Peloton in 2018 – following OPEN’s acquisition with Amulet Capital Partners – and one last year with HEOR and market access firm Pharmerit.

Communication 78

Communication 78

pharmaphorum

DECEMBER 6, 2022

Work should also be undertaken on making product studies generalisable between national jurisdictions, the design of real-world evidence (RWE), healthcare evaluation outcomes research (HEOR) and clinical workflow pilot studies, and how DTx can be adapted for different languages and cultures.

Documentation 80

Documentation 80

European Pharmaceutical Review

SEPTEMBER 2, 2022

This article explores just one aspect of the RMP, that of RMMs, and how their effectiveness is measured with Dr Sophie Jouaville, an associate principal at IQVIA working on the design and oversight of non-interventional real-world evidence (RWE) safety and health economics and outcomes research (HEOR) studies.

Adverse Reactions 76

Adverse Reactions Documentation Medical Schools Packaging 76

pharmaphorum

AUGUST 17, 2021

AXON is expecting to make several appointments in the US in the coming months to support existing clients and potential new opportunities, as we expand our work in medical affairs, clinical trial services, HEOR and real-world evidence, and public relations.

Communication 98

Communication 98

pharmaphorum

MARCH 30, 2021

So HEOR and market access must be involved up front, but she advocates a wider collaborative approach which also includes external perspectives from payers, policy makers and influential groups such as ISPOR. We had a lot of different perspectives from people in HEOR, market access, regulatory and marketing.

Communication 59

Communication Labelling 59

pharmaphorum

JUNE 8, 2022

Combining our skills and experiences across HEOR, market access, and policy will allow us to partner with clients to provide a deeper set of integrated capabilities not offered by other firms,” says David Sykes, President of Policy, Access, Value, and Evidence at FH. . We are delighted to welcome the Avalere team to FH.

Communication 52

Communication 52

Viseven

NOVEMBER 17, 2022

The role of medical affairs in pharmaceutical companies. The department of medical affairs encompasses an array of roles and responsibilities.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies Documentation 52

pharmaphorum

DECEMBER 15, 2022

Thousands more UK patients with idiopathic pulmonary fibrosis (IPF) will now be eligible for treatment with Boehringer Ingelheim’s Ofev, following new guidance from health technology assessment agency NICE.

Labelling 101

Labelling Hospitals 101

pharmaphorum

SEPTEMBER 6, 2022

NICE has said it is unable to recommend NHS use of AstraZeneca’s Lynparza for some patients with prostate cancer, after failing to reach an agreement on price with the drugmaker.

Chemotherapy 109

Chemotherapy 109

pharmaphorum

JUNE 20, 2022

Thousands more people with breast cancer in England look set to be eligible for routine treatment with Eli Lilly’s Verzenios, after new guidance from NICE backed use of the drug after surgery for early-stage tumours.

109

109

pharmaphorum

SEPTEMBER 22, 2022

BeiGene’s BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine NHS use in England and Wales to treat Waldenström macroglobulinaemia (WM) – a rare form of non-Hodgkin lymphoma (NHL).

Adverse Reactions 97

Adverse Reactions Documentation Hospitals 97

pharmaphorum

NOVEMBER 16, 2022

NICE has recommended that three COVID-19 therapies can continue to be used to treat patients – Pfizer’s Paxlovid, Roche’s RoActemra and Eli Lilly’s Olumiant – but turned down another five in draft guidance published this week.

Vaccines 91

Vaccines Documentation 91

pharmaphorum

NOVEMBER 25, 2022

The European Commission has provided around €7 million ($7.2 million) in funding to a new project that aims to boost the ability of hospitals within the EU to collect real-world data (RWD) to gauge the effectiveness of novel cancer therapies.

Hospitals 89

Hospitals 89

pharmaphorum

AUGUST 19, 2021

Novartis’ Rydapt has become the first and only licensed treatment for rare and life-threatening blood disorder systemic mastocytosis (SM) to be cleared for routine NHS use, after getting a green light from NICE.

123

123

pharmaphorum

JULY 15, 2022

Health technology assessment (HTA) agency NICE has finalised its guidance on Amarin’s Vazkepa, clearing the path for GPs to start prescribing the drug in up to 425,000 NHS patients at high cardiovascular risk because of raised triglyceride levels. mmol/litre or above) in their blood who are already taking statins.

Documentation 98

Documentation 98

pharmaphorum

FEBRUARY 8, 2022

Novo Nordisk’s new obesity therapy Wegovy has been recommended for routine NHS use by UK cost-effectiveness watchdog NICE, but in a narrower group of patients than is covered by its MHRA-approved label.

Labelling 104

Labelling 104

Viseven

FEBRUARY 6, 2023

Also, social media platforms can provide pharma marketers and HEORs with large amounts of valuable medical information that may help in understanding the preferences of healthcare consumers and HCPs. Finally, social networks are a powerful tool that allows companies to provide education or advertise current social projects.

Communication 75

Communication 75

pharmaphorum

DECEMBER 22, 2022

One of the most highly-anticipated developments in pharma next year will be the FDA’s verdict on Eisai’s accelerated application for lecanemab in Alzheimer’s disease, due early in January.

FDA 76

FDA 76

pharmaphorum

JULY 14, 2022

Cost-effectiveness watchdog NICE has recommended routine NHS use of two new therapies for women with advanced breast cancer – Gilead’s Trodelvy and Novartis’ Piqray – in England. .

Chemotherapy 86

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Labelling 86

pharmaphorum

DECEMBER 17, 2021

After three years of availability via the Cancer Drugs Fund (CDF), MSD’s checkpoint inhibitor Keytruda has now been approved for routine NHS use after surgery for people with melanoma to prevent the cancer returning.

96

96

pharmaphorum

APRIL 20, 2021

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator. .

Hospitals 109

Hospitals Documentation 109

pharmaphorum

JULY 9, 2021

Orchard Therapeutics’ gene therapy for rare childhood disease metachromatic leukodystrophy (MLD) Libmeldy has been rejected for NHS use by NICE in draft guidance.

Compounding 104

Compounding Immunization 104

pharmaphorum

OCTOBER 21, 2021

UK cost-effectiveness watchdog NICE is set to recommend NHS use of Alnylam’s gene-silencing therapy Givlaari in England and Wales for the rare disease acute hepatic porphyria (AHP), after its advisors issued a positive verdict on the drug.

Documentation 94

Documentation Compounding Hospitals 94

pharmaphorum

JUNE 30, 2021

bluebird bio’s sickle cell disease (CD) gene therapy LentiGlobin is the latest recipient of an ‘innovation passport’ introduced in the UK earlier this year to speed up NHS access to promising new medicines.

FDA 98

FDA 98

pharmaphorum

NOVEMBER 16, 2021

NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharma’s Ontozry.

Documentation 87

Documentation 87

pharmaphorum

SEPTEMBER 1, 2021

Novartis’ cholesterol-lowering drug Leqvio will be made available on the NHS in England and Wales, and could help to prevent up to 30,000 deaths, according to NICE.

92

92

pharmaphorum

DECEMBER 21, 2022

AstraZeneca and Daiichi Sankyo’s Enhertu will become an option for hundreds more people with breast cancer in England and Wales, thanks to new guidance from NICE that will make it available via the Cancer Drugs Fund.

Chemotherapy 62

Chemotherapy 62

pharmaphorum

NOVEMBER 7, 2022

Draft guidance in the UK has provisionally recommended that digital cognitive behavioural therapy (CBT) apps can be used within the NHS to treat children and young people with mild to moderate anxiety.

Communication 62

Communication 62

pharmaphorum

MARCH 8, 2021

NHS patients in England will not be able to get access to AstraZeneca’s PARP inhibitor Lynparza if they have BRCA-positive advance prostate cancer, according to draft guidance from NICE.

Chemotherapy 94

Chemotherapy Labelling FDA 94

pharmaphorum

MARCH 9, 2022

There isn’t enough evidence to support the use of Merck & Co/MSD’s Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, according to the UK cost effectiveness watchdog NICE.

Chemotherapy 73

Chemotherapy 73

pharmaphorum

JANUARY 19, 2023

Alnylam’s gene-silencing drug Amvuttra has been recommended as a treatment for hereditary transthyretin-related (ATTR) amyloidosis by NICE, paving the way for the drug to be made available on the NHS in England and Wales.

Hospitals 52

Hospitals 52

pharmaphorum

JANUARY 13, 2023

Cholesterol-lowering statin drugs could be available to millions more patients in the UK, if new recommendations from health technology assessment (HTA) organisation NICE are implemented.

Documentation 52

Documentation 52

pharmaphorum

DECEMBER 24, 2020

Just a few weeks after its EU approval for heart failure, AstraZeneca’s Forxiga has been backed by NICE for this use by the NHS in England and Wales.

FDA 98

FDA 98

pharmaphorum

MAY 25, 2022

Around 100 patients in England and Wales with triple negative breast cancer (TNBC) that has spread to other parts of the body could soon access treatment with Merck & Co/MSD’s Keytruda, on the recommendation of cost-effectiveness agency NICE.

Chemotherapy 62

Chemotherapy Immunization 62

pharmaphorum

MAY 13, 2022

Around 4,500 women in the UK will be eligible for treatment with Gedeon Richter’s once-daily oral therapy Ryeqo, after NICE backed the GnRH antagonist to treat heavy menstrual bleeding associated with uterine fibroids.

62

62

pharmaphorum

NOVEMBER 24, 2022

Bristol-Myers Squibb’s Opdivo has been recommended as a treatment for around 3,000 people with rare forms of gastro-oesophageal cancer via the NHS in England and Wales.

Chemotherapy 52

Chemotherapy Documentation 52

pharmaphorum

JANUARY 19, 2021

The Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of lung cancer, almost seven months after NICE backed the drug in England.

Chemotherapy 85

Chemotherapy Immunization 85